Last updated: August 20, 2026
Key Takeaways
- Normalized EBITDA is the primary metric institutional buyers use to compare dental practices after removing owner-specific pay and one-time expenses.
- In 2026, EBITDA multiples range from 5x–7x for smaller practices up to 10x–12x+ for platform-grade practices with $5M+ EBITDA, with institutional buyers often paying meaningful premiums over private buyers.
- Thorough normalization replaces owner compensation with market-rate associate costs, removes personal expenses, and documents every add-back so it can withstand quality-of-earnings review.
- Practices with strong hygiene production, effective associate utilization, multi-location infrastructure, and commercial payer mix often achieve higher EBITDA multiples and attract stronger institutional offers.
- McLerran & Associates provides side-by-side valuations comparing your practice’s worth in both private-buyer and institutional markets, so you can schedule a free, confidential discovery call and shape the narrative around your EBITDA before you sell.
EBITDA Benchmarks for Dental Practices in 2026
A well-run dental practice often targets a normalized EBITDA margin of 30% or higher after adjusting owner compensation to a market-rate associate equivalent. The absolute EBITDA figure, not just the margin, can be one of the main factors that determines which buyer tier and multiple range apply to your practice.
The table below summarizes 2026 EBITDA multiple ranges by practice scale and buyer type. These ranges draw from the PPR Multiple-Decoder Framework (Private Practice Research, May 2026) and FOCUS Investment Banking’s December 2025 report.
| Practice Scale (Normalized EBITDA) | Private / Individual Buyer Range | Institutional Buyer Range |
|---|---|---|
| Sub-$1M EBITDA (solo / add-on) | 5x–7x | 5x–7x (small institutional tuck-in) |
| $1M–$3M EBITDA (regional add-on) | 7x–9x (associate-led groups) | 7x–9x (regional institutional add-on) |
| $3M–$5M EBITDA (emerging platform) | Less common at this scale | 9x–11x (emerging platform / strategic regional) |
| $5M+ EBITDA (platform-grade) | Rarely applicable | 10x–12x+ (institutional platform acquisition) |
Specialty practices can command different ranges depending on buyer demand and consolidation activity in that segment. FOCUS Investment Banking reports that demand in 2026 remains very high for specialty dental groups including pediatrics, orthodontics, oral surgery, periodontics, and endodontics, with specialty platforms often reaching the upper end of institutional multiple ranges. Institutional buyers can pay a substantial premium compared to private buyers for the same practice, so a side-by-side comparison from an advisor who works both markets can be essential before you choose a path. Before you compare offers across buyer types, you benefit from understanding which earnings metric each buyer uses to evaluate your practice.
SDE vs. EBITDA for Dental Practice Valuation
The earnings metric that applies to your practice usually depends on who is buying it. SDE (Seller’s Discretionary Earnings) is the standard for owner-operator transactions, while normalized EBITDA is the primary language institutional buyers use.
SDE equals net income plus the owner’s full compensation package, including salary, benefits, and perks, plus one-time and non-operating expenses. It reflects the total economic benefit flowing to a single owner-operator. Private buyers in 2026 typically pay 2.5x–5.0x SDE for smaller owner-dentist practices.
Normalized EBITDA, by contrast, replaces the owner’s actual compensation with the market-rate cost of a replacement associate dentist. This approach produces a lower, more conservative earnings figure, yet one that institutional buyers can underwrite across a portfolio. Institutional buyers typically target practices with sufficient post-doctor-compensation EBITDA, and they require normalized EBITDA because they need to model what the practice earns after they install a clinical replacement for the departing owner.
The practical implication is straightforward. If your practice is in the $1M–$1.5M revenue range, both metrics may be relevant depending on which buyer pool you pursue. McLerran & Associates builds both calculations up front so you can compare your worth in each market before you commit to a path.
Normalization Steps for a Dental Practice Sale
Normalization restates a practice’s financials to reflect ongoing profitability under new ownership. This process removes the owner’s personal financial decisions from the income statement so buyers evaluate the business, not the lifestyle. Every add-back must be documented and defensible. Industry analyses have found financial discrepancies in more than 40% of small business acquisitions, with add-back inflation as a primary mechanism, so institutional buyers deploy quality-of-earnings (QoE) teams to scrutinize every line.
The checklist below reflects the diligence-grade normalization process McLerran & Associates performs on every engagement. It draws on frameworks from TUSK Practice Sales, Auxo Capital Advisors, and Precision Dental Analytics.
- Owner compensation normalization. Replace the owner’s actual W-2 and distributions with the market-rate cost of a replacement associate dentist, typically 28%–32% of the owner’s clinical production for a general practitioner. This adjustment is often the largest and frequently the most contested in QoE review.
- Personal expenses run through the practice. Add back non-business costs such as personal vehicle leases, personal cell phone and internet, club memberships, personal travel labeled as continuing education, and owner life insurance premiums. Personal expenses run through the practice typically total $30K to $150K per year for owner-operated practices.
- Family member payroll above market rate. Spousal and family payroll for non-working or under-working relatives is normalized as a direct EBITDA add-back. When a family member performs a genuine function, only the above-market portion is added back.
- Non-recurring and one-time items. Add back items such as litigation settlements, one-time legal or consulting fees, emergency equipment replacement, and pre-sale preparation costs, provided they are verified as non-recurring across 3 years of financials.
- Related-party rent adjustment. When the owner also owns the building, normalize rent to an arm’s-length market rate.
- Associate ramp-up compensation. Normalize associate compensation during ramp-up periods to market rates so earnings reflect a steady-state cost structure.
- Deferred capital expenditure (CapEx). Aging operatories, missing technology, or deferred equipment replacement may be treated as a negative adjustment against enterprise value by institutional buyers, which functions as a deduction rather than an add-back.
- Hygiene and associate production benchmarking. Normalize revenue to a net collections methodology and flag any phantom PPO write-offs or below-market staff compensation that distort the true margin profile.
A weak normalization analysis often fails during due diligence because buyers challenge unsupported adjustments. McLerran’s CPA-led process unpacks every add-back before the deal goes to market and builds documentation that can withstand scrutiny. When the homework is completed up front, the number tends to hold when buyers look under the hood and the agreed value is less likely to be re-traded at closing.
Operational Drivers of Higher EBITDA Multiples in 2026
Multiple uplift in 2026 often comes from operational characteristics that reduce buyer risk and increase the transferability of revenue after the selling doctor exits. Two factors can be some of the main drivers, with several supporting elements that also matter.
- Hygiene production as a share of collections. Practices with strong hygiene revenue as a share of collections can receive EBITDA multiple premiums and attract stronger institutional offers because recurring hygiene visits signal a stable, transferable patient base. In a well-run general dental practice, hygiene production typically represents approximately 30% of total practice production.
- Associate utilization and reduced owner dependence. Practices with reduced owner dependence can achieve EBITDA multiple premiums, while practices where the owner produces 90% or more of revenue can face a valuation reduction. Adding even one producing associate can move an owner-dependent practice up approximately one full turn of EBITDA.
- Multi-location infrastructure. Practices with 3 or more locations and shared management infrastructure can qualify for platform-grade pricing of 9x–11x EBITDA versus 5x–8x for single-location add-ons.
- Payer mix. A commercial-weighted payer mix supports the top end of EBITDA multiples, while heavy Medicaid reliance or shrinking PPO fees can cap the achievable multiple.
- Digital workflow integration. Dental groups with integrated digital workflows, such as digital radiography, intraoral scanning, and cloud-based practice management, often achieve stronger margin resilience and higher multiples.
- Patient retention and reappointment rates. Practices with high patient retention rates, such as strong hygiene reappointment performance, can achieve stronger valuation outcomes because of improved revenue predictability and stability.
These metrics are the same variables institutional buyers model during diligence. Improving them before going to market can be the difference between a mid-range and a top-of-range multiple outcome.
Comparing Doctor-to-Doctor and Institutional EBITDA Outcomes
Your ideal transition path often depends on your practice’s scale, your financial goals, and how much you want to remain involved after the sale. The table below compares the 2 primary paths on dimensions that tend to matter most to premier practice owners.
| Dimension | Doctor-to-Doctor (Private Buyer) | Institutional Affiliation |
|---|---|---|
| Cash at close | 100% of agreed price at closing, no holdbacks or earnouts | Typically 51%–85% cash at close, remainder in equity or earnout |
| Equity upside | None, full exit at closing | Rollover equity in institutional platform with potential upside at recapitalization |
| Work-back expectations | Short transition of 30–90 days, seller exits completely | Typically 2–5 year employment agreement post-close |
| Headline valuation range | Generally lower, capped by individual buyer financing limits | 20%–40% higher headline for strong EBITDA practices, with a portion often deferred |
The institutional path’s higher headline number does not always create a better outcome. As much as 40% of an institutional deal can be paid in equity rather than cash, which means you are effectively investing in the platform’s future performance. Vetting that investment can be as important as negotiating the price. McLerran & Associates helps owners review a buyer’s profitability, leadership, and financial backing before any offer is accepted, and the firm has blacklisted buyers known for poor post-close environments.
Re-trade risk is one of the most underappreciated threats in an institutional transaction. A buyer’s QoE team will challenge every add-back in your normalization schedule. If the EBITDA analysis was not built to institutional standards before the deal went to market, the buyer can use diligence to chip the price down, often after the seller has invested months of time and emotional energy. McLerran’s CPA-led quality-of-earnings defense aims to hold the agreed value through diligence by anticipating likely challenges before the buyer raises them and by reminding buyers, in a professional way, that other vetted bidders are waiting if they attempt to re-trade.
Schedule a free, confidential discovery call with McLerran & Associates to receive a side-by-side valuation that quantifies your practice’s worth in both the private-buyer and institutional markets. That context helps you choose your path with full information rather than a guess.
Conclusion: Shaping the Story Your EBITDA Tells
In 2026, the lower-middle market remains firm, and many practice owners receive multiple competitive offers from a robust buyer universe of DSOs and private equity groups seeking quality acquisitions. Demand for premier, Class A practices sits near all-time highs, and expiring tax provisions in 2026 are creating urgency among sellers to transact before rates change. This window appears real, yet owners with a diligence-grade EBITDA analysis and a competitive process behind them are often the ones who fully capture it.
McLerran & Associates has guided owners through roughly 2,000 successful practice sales and approximately $2 billion in closed transaction volume, with a transaction rate of roughly 85%–90% versus an industry norm closer to 35%–40%. The firm works private-buyer and institutional deals in roughly equal measure, which makes it one of the few advisors that can deliver a genuine side-by-side comparison. Every engagement begins with an ironclad, CPA-led EBITDA analysis that is designed not to be re-traded when buyers look under the hood.
Owners who are still deciding whether to sell can explore options in a structured setting. Join the McLerran M&A Summit, October 29–30, 2026, a dental-only event built for owners who have not yet made a decision. Attendees receive 4 CE credits and a complimentary practice valuation (a $2,500 value) and leave with a clearer picture of their options before committing to anything.
Schedule a free, confidential discovery call with McLerran & Associates, or call (512) 900-7989 or email info@dentaltransitions.com. The biggest financial decision of your career can benefit from having the most experienced dental-only sell-side advisor in the country on your side.
Frequently Asked Questions
What is the difference between normalized EBITDA and SDE for a dental practice, and which one should I use?
Normalized EBITDA and SDE (Seller’s Discretionary Earnings) both address what a practice actually earns, yet they do so for different audiences. SDE adds back the owner’s full compensation package to net income, producing the total economic benefit available to a single owner-operator. It is the standard metric for doctor-to-doctor transactions where the buying dentist will step into the owner’s chair and capture those same earnings.
As explained earlier, normalized EBITDA adjusts for replacement-dentist costs rather than actual owner compensation, which yields the conservative earnings figure institutional buyers require for portfolio modeling. If your practice is in the $1M–$1.5M revenue range, both metrics may be relevant depending on which buyer pool you enter. McLerran & Associates builds both calculations as part of every engagement so you can compare your worth in each market before you choose a path.
How long does a dental practice sale typically take from start to close?
The sale timeline varies meaningfully by transaction type. A doctor-to-doctor sale through a well-run brokered process typically runs several months from valuation to close, with the seller working back roughly 4 to 8 weeks after closing before exiting completely.
A DSO or private equity affiliation usually involves a more structured process. McLerran’s competitive bid process typically runs 45–60 days and generates around 10 offers, after which the field narrows to in-person meetings with the top finalists. Once a letter of intent is signed, institutional due diligence typically lasts 60–90 days before closing.
Owners are generally advised to begin preparation 2 to 5 years ahead of their target close date, although the active sale process itself often takes 6–12 months. Many owners use that time to add provider depth, clean up financials, and address operational gaps that could suppress the multiple. If you are not ready to sell today, McLerran will complete a comprehensive valuation and update it for free a year later rather than push you into a deal before the timing is right.
What makes a dental practice “DSO-ready,” and how does it affect my valuation?
DSO-readiness describes a cluster of operational characteristics that reduce a buyer’s risk and increase the likelihood that revenue transfers cleanly after the selling doctor exits. The most important factors are associate utilization and hygiene department strength. Practices that have implemented the provider-depth strategies discussed earlier are significantly more attractive than solo-producer practices, and hygiene production above the benchmark mentioned earlier signals a stable, recurring patient base.
Beyond those 2 drivers, institutional buyers look for a commercial-weighted payer mix, integrated digital workflows, strong patient retention metrics, and systems that run independently of the owner. Practices that score well on these dimensions can achieve meaningfully higher EBITDA multiples than owner-dependent practices at the same revenue level.
Many of these improvements require 24 months or more to appear in the trailing financial statements that buyers evaluate during diligence. Starting the preparation process early, with a clear picture of where your practice stands today, can have a direct and significant impact on your eventual sale price.
How does McLerran & Associates protect my valuation through due diligence?
The most common way a dental practice deal loses value is through the re-trading dynamic described earlier in the article. McLerran protects against this in 2 main ways.
First, the firm builds a diligence-grade, CPA-led EBITDA analysis before the deal goes to market, unpacking every add-back, documenting every adjustment, and anticipating the challenges a buyer’s QoE team is likely to raise. Because the homework is done up front, the numbers are more likely to hold when buyers scrutinize them.
Second, McLerran runs a competitive process that generates multiple offers simultaneously. This structure allows the firm to remind any buyer who attempts to re-trade that other vetted bidders are waiting. That competitive tension can be one of the most powerful protections a seller has, and it is only available when an advisor has created genuine competition rather than a single-buyer negotiation.
Is now a good time to sell my dental practice?
Demand for premier dental practices in 2026 remains strong, and valuations sit near all-time highs for well-run, Class A practices. The buyer universe includes numerous DSOs and private equity groups actively seeking quality acquisitions, and the lower-middle market has seen multiple competitive offers for practices that go through a structured process.
There is also a tax-related timing consideration. Expiring tax provisions in 2026 are creating urgency among some sellers to transact before rates potentially change, which could affect after-tax proceeds. At the same time, “now” is the right time only if your practice is positioned to command a strong multiple, and that depends on your specific numbers, operational profile, and goals.
McLerran & Associates will provide an honest assessment of where your practice stands today, what it might take to maximize your outcome, and whether waiting another year to improve certain metrics would be worth the delay. If you are not ready, the firm will update your valuation for free rather than push you into a transaction before the timing serves you.
